CMS assigns Q codes to procedures, services, and supplies on a temporary basis. When a permanent code is assigned, the Q code is deleted and cross-referenced.
Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg
Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg
Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg
Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg
Injection, ustekinumab-auub (wezlana), biosimilar, subcutaneous, 1 mg
Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg
Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg
Injection, adalimumab-fkjp, biosimilar, 1 mg
Injection, adalimumab-aaty, biosimilar, 1 mg
Injection, adalimumab-ryvk biosimilar, 1 mg
Continued
Injection, adalimumab-adbm, biosimilar, 1 mg
Injection, adalimumab-aacf (idacio), biosimilar, 1 mg
Injection, adalimumab-afzb (abrilada), biosimilar, 1 mg
Injection, trastuzumab-strf (hercessi), biosimilar, 10 mg
Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg
Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram
Injection, aflibercept-abzv (enzeevu), biosimilar, 1 mg
Injection, aflibercept-mrbb (ahzantive), biosimilar, 1 mg
Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg
Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg
Injection, aflibercept-yszy (opuviz), biosimilar, 1 mg
Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg
Injection, aflibercept-jbvf (yesafili), biosimilar, 1 mg
Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg
Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg
Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg
Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg
Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg
Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg
Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg
Continued
Injection, ustekinumab-hmny (starjemza), biosimilar, 1 mg
New
Injection, denosumab-mobz (oziltus), biosimilar, 1 mg
New
Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg
New
Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg
New
Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg
New
Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg
New
Injection, aflibercept-boav (eydenzelt), biosimilar, 1 mg
New
Injection, denosumab-mobz (boncresa), biosimilar, 1 mg
New
Assessment by chaplain services
Counseling, individual, by chaplain services
Counseling, group, by chaplain services
Department of veterans affairs whole health partner services
Injection, sulfur hexafluoride lipid microspheres, per ml
Low osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml
Injection, iron-based magnetic resonance contrast agent, per ml
Oral magnetic resonance contrast agent, per 100 ml
Injection, perflexane lipid microspheres, per ml
Injection, octafluoropropane microspheres, per ml
Injection, perflutren lipid microspheres, per ml
High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml